VOLUME: 17 NO: 3 YEAR: 2020

Indexed in PMC and Web of Science
ULAKBİM, Tr Dizin, Scopus

ISSN: 1304-530X

# TURKISH JOURNAL OF PHARMACEUTICAL SCIENCES

An Official Journal of the Turkish Pharmacists' Association, Academy of Pharmacy

TURKISH
JOURNAL OF PHARMACEUTICAL SCIENCES

## Editor-in-Chief

Prof. Terken BAYDAR, Ph.D., E.R.T.
orcid.org/0000-0002-5497-9600
Hacettepe University, Faculty of Pharmacy,
Department of Toxicology, Ankara, TURKEY
tbaydar@hacettepe.edu.tr

## Associate Editors

Prof. Samiye YABANOĞLU ÇİFTÇİ, Ph.D.
orcid.org/0000-0001-5467-0497
Hacettepe University, Faculty of Pharmacy,
Department of Biochemistry, Ankara, TURKEY
samiye@hacettepe.edu.tr

Assoc. Prof. Pınar ERKEKOĞLU, Ph.D.
orcid.org/0000-0003-4713-7672
Hacettepe University, Faculty of Pharmacy,
Department of Toxicology, Ankara, TURKEY
erkekp@hacettepe.edu.tr

## Editorial Board

Prof. Fernanda BORGES, Ph.D.
orcid.org/0000-0003-1050-2402
Porto University, Faculty of Sciences, Department of Chemistry and Biochemistry, Porto, PORTUGAL
fborges@fc.up.pt

Prof. Bezhan CHANKVETADZE, Ph.D.
orcid.org/0000-0003-2379-9815
Ivane Javakhishvili Tbilisi State University, Institute of Physical and Analytical Chemistry, Tbilisi, GEORGIA
jpba_bezhan@yahoo.com

Prof. Dietmar FUCHS, Ph.D.
orcid.org/0000-0003-1627-9563
Innsbruck Medical University, Center for Chemistry and Biomedicine, Institute of Biological Chemistry, Biocenter, Innsbruck, AUSTRİA
dietmar.fuchs@i-med.ac.at

Prof. Satyajit D. Sarker, Ph.D.
orcid.org/0000-0003-4038-0514
Liverpool John Moores University, Liverpool, UNITED KINGDOM
S.Sarker@ljmu.ac.uk

Prof. Luciano SASO, Ph.D.
orcid.org/0000-0003-4530-8706
Sapienze University, Faculty of Pharmacy and Medicine, Department of Physiology and Pharmacology "Vittorio Erspamer", Rome, ITALY
luciano.saso@uniroma1.it

Prof. Rob VERPOORTE, Ph.D.
orcid.org/0000-0001-6180-1424
Leiden University, Natural Products Laboratory, Leiden, NETHERLANDS
verpoort@chem.leidenuniv.nl

## Advisory Board

**Prof. Nurettin ABACIOĞLU, Ph.D.**
Kyrenia University, Faculty of Pharmacy, Department of Pharmacology, Girne, TRNC, CYPRUS

**Prof. Kadriye BENKLİ, Ph.D.**
Girne American University, Faculty of Pharmacy, Department of Pharmaceutical Chemistry, Girne, TRNC, CYPRUS

**Prof. Arzu BEŞİKCİ, Ph.D.**
Ankara University, Faculty of Pharmacy, Department of Pharmacology, Ankara, TURKEY

**Prof. Erem BİLENSOY, Ph.D.**
Hacettepe University, Faculty of Pharmacy, Department of Pharmaceutical Technology, Ankara, TURKEY

**Prof. Hermann BOLT, Ph.D.**
Dortmund University, Leibniz Research Centre, Institute of Occupational Physiology, Dortmund, GERMANY

**Prof. Erdal CEVHER, Ph.D.**
İstanbul University Faculty of Pharmacy, Department of Pharmaceutical Technology, İstanbul, TURKEY

**Prof. Nevin ERK, Ph.D.**
Ankara University, Faculty of Pharmacy, Department of Analytical Chemistry, Ankara, TURKEY

**Prof. Jean-Alain FEHRENTZ, Ph.D.**
Montpellier University, Faculty of Pharmacy, Institute of Biomolecules Max Mousseron, Montpellier, FRANCE

**Prof. Joerg KREUTER, Ph.D.**
Johann Wolfgang Goethe University, Faculty of Pharmacy, Institute of Pharmaceutical Technology, Frankfurt, GERMANY

**Prof. Christine LAFFORGUE, Ph.D.**
Paris-Sud University, Faculty of Pharmacy, Department of Dermopharmacology and Cosmetology, Paris, FRANCE

**Prof. Şule APİKOĞLU RABUŞ, Ph.D.**
Marmara University, Faculty of Pharmacy, Department of Clinical Pharmacy, İstanbul, TURKEY

**Prof. Robert RAPOPORT, Ph.D.**
Cincinati University, Faculty of Pharmacy, Department of Pharmacology and Cell Biophysics, Cincinati, USA

**Prof. Wolfgang SADEE, Ph.D.**
Ohio State University, Center for Pharmacogenomics, Ohio, USA

**Prof. Hildebert WAGNER, Ph.D.**
Ludwig-Maximilians University, Center for Pharmaceutical Research, Institute of Pharmacy, Munich, GERMANY

**Assoc. Prof. Hande SİPAHİ, Ph.D.**
Yeditepe University, Faculty of Pharmacy, Department of Toxicology, İstanbul, TURKEY

**Assoc. Prof. İpek SÜNTAR, Ph.D.**
Gazi University, Faculty of Pharmacy, Department of Pharmacognosy, Ankara, TURKEY

TURKISH
JOURNAL OF PHARMACEUTICAL SCIENCES

## Baş Editör

Terken BAYDAR, E.R.T. , Prof. Dr.
orcid.org/0000-0002-5497-9600
Hacettepe Üniversitesi, Eczacılık Fakültesi,
Toksikoloji Bölümü, Ankara, TÜRKİYE
tbaydar@hacettepe.edu.tr

## Yardımcı Editörler

Samiye YABANOĞLU ÇİFTÇİ, Prof. Dr.
orcid.org/0000-0001-5467-0497
Hacettepe Üniversitesi, Eczacılık Fakültesi ,
Biyokimya Bölümü, Ankara, TÜRKİYE
samiye@hacettepe.edu.tr

Pınar ERKEKOĞLU, Doç. Dr.
orcid.org/0000-0003-4713-7672
Hacettepe Üniversitesi, Eczacılık Fakültesi,
Toksikoloji Bölümü, Ankara, TÜRKİYE
erkekp@hacettepe.edu.tr

## Editörler Kurulu

Fernanda BORGES, Prof. Dr.
orcid.org/0000-0003-1050-2402
Porto Üniversitesi, Fen Fakültesi, Kimya ve Biyokimya Anabilim Dalı, Porto, PORTEKİZ
fborges@fc.up.pt

Bezhan CHANKVETADZE, Prof. Dr.
orcid.org/0000-0003-2379-9815
Ivane Javakhishvili Tiflis Devlet Üniversitesi, Fiziksel ve Analitik Kimya Enstitüsü, Tiflis, GÜRCİSTAN
jpba_bezhan@yahoo.com

Dietmar FUCHS, Prof. Dr.
orcid.org/0000-0003-1627-9563
Innsbruck Tıp Üniversitesi, Kimya ve Biyotıp Merkezi, Biyolojik Kimya Enstitüsü, Biocenter, Innsbruck, AVUSTURYA
dietmar.fuchs@i-med.ac.at

Satyajit D. Sarker, Prof. Dr.
orcid.org/0000-0003-4038-0514
Liverpool John Moores Üniversitesi, Liverpool, BIRLEŞIK KRALLIK
S.Sarker@ljmu.ac.uk

Luciano SASO, Prof. Dr.
orcid.org/0000-0003-4530-8706
Sapienza Üniversitesi, Eczacılık ve Tıp Fakültesi, Fizyoloji ve Farmakoloji Anabilim Dalı "Vittorio Erspamer", Roma, İTALYA
luciano.saso@uniroma1.it

Rob VERPOORTE, Prof. Dr.
orcid.org/0000-0001-6180-1424
Leiden Üniversitesi, Doğal Ürünler Laboratuvarı, Leiden, HOLLANDA
verpoort@chem.leidenuniv.nl

## Danışma Kurulu

**Nurettin ABACIOĞLU, Prof. Dr.**
Girne Üniversitesi, Eczacılık Fakültesi, Farmakoloji Anabilim Dalı, Girne, TRNC, KIBRIS

**Kadriye BENKLİ, Prof. Dr**
Girne Amerikan Üniversitesi, Eczacılık Fakültesi, Farmasötik Kimya Bölümü, Girne, TRNC, KIBRIS

**Arzu BEŞİKCİ, Prof. Dr.**
Ankara Üniversitesi, Eczacılık Fakültesi, Farmakoloji Anabilim Dalı, Ankara, TÜRKİYE

**Erem BİLENSOY, Prof. Dr.**
Hacettepe Üniversitesi, Eczacılık Fakültesi, Farmasötik Teknoloji Bölümü, Ankara, TÜRKİYE

**Hermann BOLT, Prof. Dr.**
Dortmund Üniversitesi, Leibniz Araştırma Merkezi, Mesleki Fizyoloji Enstitüsü, Dortmund, ALMANYA

**Erdal CEVHER, Prof. Dr.**
İstanbul Üniversitesi Eczacılık Fakültesi, Farmasötik Teknoloji Bölümü, İstanbul, TÜRKİYE

**Nevin ERK, Prof. Dr.**
Ankara Üniversitesi, Eczacılık Fakültesi, Department of Analytical Chemistry, Ankara, TÜRKİYE

**Jean-Alain FEHRENTZ, Prof. Dr.**
Montpellier Üniversitesi, Eczacılık Fakültesi, Biyomoleküller Enstitüsü Max Mousseron, Montpellier, FRANSA

**Joerg KREUTER, Prof. Dr.**
Johann Wolfgang Goethe Üniversitesi, Eczacılık Fakültesi, Farmasötik Teknoloji Enstitüsü, Frankfurt, ALMANYA

**Christine LAFFORGUE, Prof. Dr.**
Paris-Sud Üniversitesi, Eczacılık Fakültesi, Dermofarmakoloji ve Kozmetoloji Bölümü, Paris, FRANSA

**Şule APİKOĞLU RABUŞ, Prof. Dr.**
Marmara Üniversitesi, Eczacılık Fakültesi, Klinik Eczacılık Bölümü, İstanbul, TÜRKİYE

**Robert RAPOPORT, Prof. Dr.**
Cincinnati Üniversitesi, Eczacılık Fakültesi, Farmakoloji ve Hücre Biyofiziği Bölümü, Cincinnati, ABD

**Wolfgang SADEE, Prof. Dr.**
Ohio Eyalet Üniversitesi, Farmakogenomik Merkezi, Ohio, ABD

**Hildebert WAGNER, Prof. Dr.**
Ludwig-Maximilians Üniversitesi, Farmasötik Araştırma Merkezi, Eczacılık Enstitüsü, Münih, ALMANYA

**Hande SİPAHİ, Doç. Dr.**
Yeditepe Üniversitesi, Eczacılık Fakültesi, Toksikoloji Anabilim Dalı, İstanbul, TÜRKİYE

**İpek SÜNTAR, Doç. Dr.**
Gazi Üniversitesi, Eczacılık Fakültesi, Farmakognozi Anabilim Dalı, Ankara, TÜRKİYE

# TURKISH JOURNAL OF PHARMACEUTICAL SCIENCES

## AIMS AND SCOPE

The Turkish Journal of Pharmaceutical Sciences is the only scientific periodical publication of the Turkish Pharmacists' Association and has been published since April 2004.
Turkish Journal of Pharmaceutical Sciences journal is regularly published 6 times in a year (February, April, June, August, October, December). The issuing body of the journal is Galenos Yayinevi/Publishing House level.
The aim of Turkish Journal of Pharmaceutical Sciences is to publish original research papers of the highest scientific and clinical value at an international level. The target audience includes specialists and professionals in all fields of pharmaceutical sciences.
The editorial policies are based on the "Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals (ICMJE Recommendations)" by the International Committee of Medical Journal Editors (2013, archived at http://www.icmje.org/) rules.

### Editorial Independence

Turkish Journal of Pharmaceutical Sciences is an independent journal with independent editors and principles and has no commerical relationship with the commercial product, drug or pharmaceutical company regarding decisions and review processes upon articles.

### ABSTRACTED/INDEXED IN

PubMed Central
Web of Science-Emerging Sources Citation Index (ESCI)
SCOPUS SJR
TÜBİTAK/ULAKBİM TR Dizin
Directory of Open Access Journals (DOAJ)
ProQuest
Chemical Abstracts Service (CAS)
EBSCO
EMBASE
GALE
Index Copernicus
Analytical Abstracts
International Pharmaceutical Abstracts (IPA)
Medicinal & Aromatic Plants Abstracts (MAPA)
British Library
CSIR INDIA
GOALI
Hinari
OARE
ARDI
AGORA
Türkiye Atıf Dizini
Türk Medline
UDL-EDGE
J- Gate
Idealonline
ROOTINDEXING

### OPEN ACCESS POLICY

This journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge.
Open Access Policy is based on the rules of the Budapest Open Access Initiative (BOAI) http://www.budapestopenaccessinitiative.org/. By "open access" to peer-reviewed research literature, we mean its free availability on the public internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from gaining access to the internet itself. The only constraint on reproduction and distribution, and the only role for copyright in this domain, should be to give authors control over the integrity of their work and the right to be properly acknowledged and cited.

### CORRESPONDENCE ADDRESS

All correspondence should be directed to the Turkish Journal of Pharmaceutical Sciences editorial board;

Post Address: Turkish Pharmacists' Association, Mustafa Kemal Mah 2147.Sok No:3 06510 Çankaya/Ankara, TURKEY
Phone: +90 (312) 409 81 00
Fax: +90 (312) 409 81 09
Web Page: http://turkjps.org
E-mail: teb@teb.org.tr

### PERMISSIONS

Requests for permission to reproduce published material should be sent to the publisher.
Publisher: Erkan Mor
Adress: Molla Gürani Mah. Kaçamak Sok. 21/1 Fındıkzade, Fatih, Istanbul, Turkey
Telephone: +90 212 621 99 25
Fax: +90 212 621 99 27
Web page: http://www.galenos.com.tr/en
E-mail: info@galenos.com.tr

### ISSUING BODY CORRESPONDING ADDRESS

Issuing Body : Galenos Yayınevi
Address: Molla Gürani Mah. Kaçamak Sk. No: 21/1, 34093 İstanbul, Turkey
Phone: +90 212 621 99 25 Fax: +90 212 621 99 27
E-mail: info@galenos.com.tr

### MATERIAL DISCLAIMER

The author(s) is (are) responsible for the articles published in the JOURNAL.
The editor, editorial board and publisher do not accept any responsibility for the articles.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

galenos yayınevi

**Galenos Publishing House**
**Owner and Publisher**
Derya Mor
Erkan Mor

**Publication Coordinator**
Burak Sever

**Web Coordinators**
Fuat Hocalar
Turgay Akpınar

**Graphics Department**
Ayda Alaca
Çiğdem Birinci
Gülşah Özgül

**Project Coordinators**
Hatice Sever
Gamze Aksoy
Saliha Tuğçe Evin
Melike Eren
Duygu Yıldırm
Pınar Akpınar

**Project Assistants**
Gülay Akın
Özlem Çelik
Rabia Palazoğlu

**Research&Development**
Mert Can Köse
Mevlüde Özlem Akgüney

**Finance Coordinator**
Sevinç Çakmak

**Publisher Contact**
**Address:** Molla Gürani Mah. Kaçamak Sk. No: 21/1
34093 İstanbul, Turkey
**Phone:** +90 (212) 621 99 25 **Fax:** +90 (212) 621 99 27
**E-mail:** info@galenos.com.tr/yayin@galenos.com.tr
**Web:** www.galenos.com.tr | Publisher Certificate Number: 14521

**Printing at:** Üniform Basım San. ve Turizm Ltd. Şti.
Matbaacılar Sanayi Sitesi 1. Cad. No: 114 34204 Bağcılar, İstanbul, Turkey
**Phone:** +90 (212) 429 10 00 | Certificate Number: 42419
**Printing Date:** June 2020
**ISSN:** 1304-530X
International scientific journal published quarterly.

TURKISH
JOURNAL OF PHARMACEUTICAL SCIENCES

# INSTRUCTIONS TO AUTHORS

Turkish Journal of Pharmaceutical Sciences journal is published 6 times (February, April, June, August, October, December) per year and publishes the following articles:

• Research articles

• Reviews (only upon the request or consent of the Editorial Board)

• Preliminary results/Short communications/Technical notes/Letters to the Editor in every field of pharmaceutical sciences.

The publication language of the journal is English.

The Turkish Journal of Pharmaceutical Sciences does not charge any article submission or processing charges.

A manuscript will be considered only with the understanding that it is an original contribution that has not been published elsewhere.

The Journal should be abbreviated as "Turk J Pharm Sci" when referenced.

The scientific and ethical liability of the manuscripts belongs to the authors and the copyright of the manuscripts belongs to the Journal. Authors are responsible for the contents of the manuscript and accuracy of the references. All manuscripts submitted for publication must be accompanied by the Copyright Transfer Form [copyright transfer]. Once this form, signed by all the authors, has been submitted, it is understood that neither the manuscript nor the data it contains have been submitted elsewhere or previously published and authors declare the statement of scientific contributions and responsibilities of all authors.

Experimental, clinical and drug studies requiring approval by an ethics committee must be submitted to the JOURNAL with an ethics committee approval report including approval number confirming that the study was conducted in accordance with international agreements and the Declaration of Helsinki (revised 2013) (http://www.wma.net/en/30publications/10policies/b3/). The approval of the ethics committee and the fact that informed consent was given by the patients should be indicated in the Materials and Methods section. In experimental animal studies, the authors should indicate that the procedures followed were in accordance with animal rights as per the Guide for the Care and Use of Laboratory Animals ( http://oacu.od.nih.gov/regs/guide/guide.pdf ) and they should obtain animal ethics committee approval.

Authors must provide disclosure/acknowledgment of financial or material support, if any was received, for the current study.

If the article includes any direct or indirect commercial links or if any institution provided material support to the study, authors must state in the cover letter that they have no relationship with the commercial product, drug, pharmaceutical company, etc. concerned; or specify the type of relationship (consultant, other agreements), if any.

Authors must provide a statement on the absence of conflicts of interest among the authors and provide authorship contributions.

All manuscripts submitted to the journal are screened for plagiarism using the 'iThenticate' software. Results indicating plagiarism may result in manuscripts being returned or rejected.

The Review Process

This is an independent international journal based on double-blind peer-review principles. The manuscript is assigned to the Editor-in-Chief, who reviews the manuscript and makes an initial decision based on manuscript quality and editorial priorities. Manuscripts that pass initial evaluation are sent for external peer review, and the Editor-in-Chief assigns an Associate Editor. The Associate Editor sends the manuscript to at least two reviewers (internal and/or external reviewers). The Associate Editor recommends a decision based on the reviewers' recommendations and returns the manuscript to the Editor-in-Chief. The Editor-in-Chief makes a final decision based on editorial priorities, manuscript quality, and reviewer recommendations. If there are any conflicting recommendations from reviewers, the Editor-in-Chief can assign a new reviewer.

The scientific board guiding the selection of the papers to be published in the Journal consists of elected experts of the Journal and if necessary, selected from national and international authorities. The Editor-in-Chief, Associate Editors may make minor corrections to accepted manuscripts that do not change the main text of the paper.

In case of any suspicion or claim regarding scientific shortcomings or ethical infringement, the Journal reserves the right to submit the manuscript to the supporting institutions or other authorities for investigation. The Journal accepts the responsibility of initiating action but does not undertake any responsibility for an actual investigation or any power of decision.

The Editorial Policies and General Guidelines for manuscript preparation specified below are based on "Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals (ICMJE Recommendations)" by the International Committee of Medical Journal Editors (2013, archived at http://www.icmje.org/).

Preparation of research articles, systematic reviews and meta-analyses must comply with study design guidelines:

CONSORT statement for randomized controlled trials (Moher D, Schultz KF, Altman D, for the CONSORT Group. The CONSORT statement revised recommendations for improving the quality of reports of parallel group randomized trials. JAMA 2001; 285: 1987-91) (http://www.consort-statement.org/);

PRISMA statement of preferred reporting items for systematic reviews and meta-analyses (Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 2009; 6(7): e1000097.) (http://www.prisma-statement.org/);

STARD checklist for the reporting of studies of diagnostic accuracy (Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, et al., for the STARD Group. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Ann Intern Med 2003;138:40-4.) (http://www.stard-statement.org/);

STROBE statement, a checklist of items that should be included in reports of observational studies (http://www.strobe-statement.org/);

MOOSE guidelines for meta-analysis and systemic reviews of observational studies (Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting Meta-analysis of observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283: 2008-12).

## GENERAL GUIDELINES

Manuscripts can only be submitted electronically through the Journal Agent website (http://journalagent.com/tjps/) after creating an account. This system allows online submission and review.

TURKISH
JOURNAL OF PHARMACEUTICAL SCIENCES

# INSTRUCTIONS TO AUTHORS

**Format:** Manuscripts should be prepared using Microsoft Word, size A4 with 2.5 cm margins on all sides, 12 pt Arial font and 1.5 line spacing.

**Abbreviations:** Abbreviations should be defined at first mention and used consistently thereafter. Internationally accepted abbreviations should be used; refer to scientific writing guides as necessary.

**Cover letter:** The cover letter should include statements about manuscript type, single-Journal submission affirmation, conflict of interest statement, sources of outside funding, equipment (if applicable), for original research articles.

## ETHICS COMMITTEE APPROVAL

The editorial board and our reviewers systematically ask for ethics committee approval from every research manuscript submitted to the Turkish Journal of Pharmaceutical Sciences. If a submitted manuscript does not have ethical approval, which is necessary for every human or animal experiment as stated in international ethical guidelines, it must be rejected on the first evaluation.

Research involving animals should be conducted with the same rigor as research in humans; the Turkish Journal of Pharmaceutical Sciences asks original approval document to show implements the 3Rs principles. If a study does not have ethics committee approval or authors claim that their study does not need approval, the study is consulted to and evaluated by the editorial board for approval.

## SIMILARITY

The Turkish Journal of Pharmaceutical Sciences is routinely looking for similarity index score from every manuscript submitted before evaluation by the editorial board and reviewers. The journal uses iThenticate plagiarism checker software to verify the originality of written work. There is no acceptable similarity index; but, exceptions are made for similarities less than 15 %.

## REFERENCES

Authors are solely responsible for the accuracy of all references.

In-text citations: References should be indicated as a superscript immediately after the period/full stop of the relevant sentence. If the author(s) of a reference is/are indicated at the beginning of the sentence, this reference should be written as a superscript immediately after the author's name. If relevant research has been conducted in Turkey or by Turkish investigators, these studies should be given priority while citing the literature.

Presentations presented in congresses, unpublished manuscripts, theses, Internet addresses, and personal interviews or experiences should not be indicated as references. If such references are used, they should be indicated in parentheses at the end of the relevant sentence in the text, without reference number and written in full, in order to clarify their nature.

References section: References should be numbered consecutively in the order in which they are first mentioned in the text. All authors should be listed regardless of number. The titles of Journals should be abbreviated according to the style used in the Index Medicus.

Reference Format

Journal: Last name(s) of the author(s) and initials, article title, publication title and its original abbreviation, publication date, volume, the inclusive page numbers. Example: Collin JR, Rathbun JE. Involutional entropion: a review with evaluation of a procedure. Arch Ophthalmol. 1978;96:1058-1064.

Book: Last name(s) of the author(s) and initials, book title, edition, place of publication, date of publication and inclusive page numbers of the extract cited.

Example: Herbert L. The Infectious Diseases (1st ed). Philadelphia; Mosby Harcourt; 1999:11;1-8.

Book Chapter: Last name(s) of the author(s) and initials, chapter title, book editors, book title, edition, place of publication, date of publication and inclusive page numbers of the cited piece.

Example: O'Brien TP, Green WR. Periocular Infections. In: Feigin RD, Cherry JD, eds. Textbook of Pediatric Infectious Diseases (4th ed). Philadelphia; W.B. Saunders Company;1998:1273-1278.

Books in which the editor and author are the same person: Last name(s) of the author(s) and initials, chapter title, book editors, book title, edition, place of publication, date of publication and inclusive page numbers of the cited piece. Example: Solcia E, Capella C, Kloppel G. Tumors of the exocrine pancreas. In: Solcia E, Capella C, Kloppel G, eds. Tumors of the Pancreas. 2nd ed. Washington: Armed Forces Institute of Pathology; 1997:145-210.

## TABLES, GRAPHICS, FIGURES, AND IMAGES

All visual materials together with their legends should be located on separate pages that follow the main text.

Images: Images (pictures) should be numbered and include a brief title. Permission to reproduce pictures that were published elsewhere must be included. All pictures should be of the highest quality possible, in

JPEG format, and at a minimum resolution of 300 dpi.

Tables, Graphics, Figures: All tables, graphics or figures should be enumerated according to their sequence within the text and a brief descriptive caption should be written. Any abbreviations used should be defined in the accompanying legend. Tables in particular should be explanatory and facilitate readers' understanding of the manuscript, and should not repeat data presented in the main text.

## MANUSCRIPT TYPES

### Original Articles

Clinical research should comprise clinical observation, new techniques or laboratories studies. Original research articles should include title, structured abstract, key words relevant to the content of the article, introduction, materials and methods, results, discussion, study limitations, conclusion references, tables/figures/images and acknowledgement sections. Title, abstract and key words should be written in both Turkish and English. The manuscript should be formatted in accordance with the above-mentioned guidelines and should not exceed 16 A4 pages.

**Title Page:** This page should include the title of the manuscript, short title, name(s) of the authors and author information. The following descriptions should be stated in the given order:

TURKISH
JOURNAL OF PHARMACEUTICAL SCIENCES

# INSTRUCTIONS TO AUTHORS

1. Title of the manuscript (Turkish and English), as concise and explanatory as possible, including no abbreviations, up to 135 characters

2. Short title (Turkish and English), up to 60 characters

3. Name(s) and surname(s) of the author(s) (without abbreviations and academic titles) and affiliations

4. Name, address, e-mail, phone and fax number of the corresponding author

5. The place and date of scientific meeting in which the manuscript was presented and its abstract published in the abstract book, if applicable

**Abstract:** A summary of the manuscript should be written in both Turkish and English. References should not be cited in the abstract. Use of abbreviations should be avoided as much as possible; if any abbreviations are used, they must be taken into consideration independently of the abbreviations used in the text. For original articles, the structured abstract should include the following sub-headings:

**Objectives:** The aim of the study should be clearly stated.

**Materials and Methods:** The study and standard criteria used should be defined; it should also be indicated whether the study is randomized or not, whether it is retrospective or prospective, and the statistical methods applied should be indicated, if applicable.

**Results:** The detailed results of the study should be given and the statistical significance level should be indicated.

**Conclusion:** Should summarize the results of the study, the clinical applicability of the results should be defined, and the favorable and unfavorable aspects should be declared.

**Keywords:** A list of minimum 3, but no more than 5 key words must follow the abstract. Key words in English should be consistent with "Medical Subject Headings (MESH)" (www.nlm.nih.gov/mesh/MBrowser.html). Turkish key words should be direct translations of the terms in MESH.

Original research articles should have the following sections:

**Introduction:** Should consist of a brief explanation of the topic and indicate the objective of the study, supported by information from the literature.

**Materials and Methods:** The study plan should be clearly described, indicating whether the study is randomized or not, whether it is retrospective or prospective, the number of trials, the characteristics, and the statistical methods used.

**Results:** The results of the study should be stated, with tables/figures given in numerical order; the results should be evaluated according to the statistical analysis methods applied. See General Guidelines for details about the preparation of visual material.

**Discussion:** The study results should be discussed in terms of their favorable and unfavorable aspects and they should be compared with the literature. The conclusion of the study should be highlighted.

Study Limitations: Limitations of the study should be discussed. In addition, an evaluation of the implications of the obtained findings/results for future research should be outlined.

**Conclusion:** The conclusion of the study should be highlighted.

**Acknowledgements:** Any technical or financial support or editorial contributions (statistical analysis, English/Turkish evaluation) towards the study should appear at the end of the article.

**References:** Authors are responsible for the accuracy of the references. See General Guidelines for details about the usage and formatting required.

**Review Articles**

Review articles can address any aspect of clinical or laboratory pharmaceuticals. Review articles must provide critical analyses of contemporary evidence and provide directions of or future research. Most review articles are commissioned, but other review submissions are also welcome. Before sending a review, discussion with the editor is recommended.

Reviews articles analyze topics in depth, independently and objectively. The first chapter should include the title in Turkish and English, an unstructured summary and key words. Source of all citations should be indicated. The entire text should not exceed 25 pages (A4, formatted as specified above).

TURKISH
JOURNAL OF PHARMACEUTICAL SCIENCES

## CONTENTS

242 Knowledge and Attitudes Among Hospital Pharmacists About COVID-19
*Hastane Eczacılarının COVID-19 Konusunda Bilgi ve Tutumları*
Emre KARA, Kutay DEMİRKAN, Serhat ÜNAL

249 Investigation of the Compressibility Characteristics of Paracetamol using "Compaction Simulator"
*"Compaction Simulator" Kullanılarak Parasetamolün Basılabilirlik Özelliklerinin İncelenmesi*
Yıldız ÖZALP, Joseph Turemi CHUNU, Nailla JIWA

254 Method Validation of Contact and Immersion TLC-bioautography for Determination of Streptomycin Sulfate in Shrimp
*Karideste Streptomisin Sülfat Tayini için Kontak ve İmmersiyon İTK-biyootografi Yönteminin Validasyonu*
Febri ANNURYANTI, Isnaeni ISNAENI, Asri DARMAWATI, Iftitahatur ROSYIDAH, Aprelita Nurelli DWIANA

259 Microemulsion Based Gel of Sulconazole Nitrate for Topical Application
*Topikal Uygulama İçin Mikroemülsiyon Esaslı Sulkonazol Nitrat Jeli*
Sumedha Prashanth PAYYAL, Narayana Charyulu ROMPICHERLA, Sandeep Divate SATHYANARAYANA, Ravi Gundadka SHRIRAM, Anoop Narayanan VADAKKEPUSHPAKATH

265 Obtaining Stem Cell Spheroids from Foreskin Tissue and the Effect of Corchorus olitorius L. on Spheroid Proliferation
*Sünnet Derisinden Kök Hücre Sferoidlerinin Elde Edilmesi ve Corchorus olitorius L.'nin Sferoid Proliferasyonuna Etkisi*
Eda BECER, Günsu SOYKUT, Hilal KABADAYI, Emil MAMMADOV, İhsan ÇALIŞ, Seda VATANSEVER

271 *In Vitro* Studies of *Jatropha curcas* L. Latex Spray Formulation for Wound Healing Applications
*Yara İyileşmesine Yönelik İn Vitro Jatropha curcas L. Lateks Sprey Formülasyonu Çalışmaları*
Kittiya TINPUN, Titpawan NAKPHENG, Alwar Ramanujam PADMAVATHI, Teerapol SRICHANA

280 Pyrophen Isolated from the Endophytic Fungus *Aspergillus fumigatus* Strain KARSV04 Synergizes the Effect of Doxorubicin in Killing MCF7 but not T47D Cells
*Endofitik Mantar Aspergillus fumigatus KARSV04 Suşundan İzole Edilen Pirofen Doksorubisinin MCF7 Hücrelerini Öldürme Etkisini Sinerjize Etmiş T47D Hücreleri Üzerindeki Etkisini Değiştirmemiştir*
Puji ASTUTI, Ika Buana JANUARTI, Naelaz Zukhruf Wakhidatul KIROMAH, Hidayah Anisa FITRI, Wahyono WAHYONO, Subagus WAHYUONO

285 Sun Protective Potential and Physical Stability of Herbal Sunscreen Developed from Afghan Medicinal Plants
*Afgan Tıbbi Bitkilerinden Geliştirilen Bitkisel Güneş Koruyucunun Güneş Koruyucu Potansiyeli ve Fiziksel Stabilitesi*
Amina AHMADY, Mohammad Humayoon AMINI, Aqa Mohammad ZHAKFAR, Gulalai BABAK, Mohammad Nasim SEDIQI

293 A Synbiotic Mixture Augmented the Efficacy of Doxepin, Venlafaxine, and Fluvoxamine in a Mouse Model of Depression
*Sinbiyotik Karışım, Fare Depresyon Modelinde Doksepin, Venlafaksin ve Fluvoksaminin Etkinliğini Artırdı*
Azadeh MESRIPOUR, Andiya MESHKATI, Valiollah HAJHASHEMI

299 *In Vitro* Antimicrobial and Antioxidant Activity of Biogenically Synthesized Palladium and Platinum Nanoparticles using *Botryococcus braunii*
*Botryococcus braunii Kullanarak Biyojenik Olarak Sentezlenmiş Paladyum ve Platin Nanopartiküllerin İn Vitro Antimikrobiyal ve Antioksidan Aktiviteleri*
Anju ARYA, Khushbu GUPTA, Tejpal Singh CHUNDAWAT

307 Mapping the Impact of a Polar Aprotic Solvent on the Microstructure and Dynamic Phase Transition in Glycerol Monooleate/Oleic Acid Systems
*Gliserol Monooleat/Oleik Asit Sistemlerinde Polar Aprotik Çözücünün Mikroyapı ve Dinamik Faz Geçişine Etkisinin Haritalanması*
Marzuka Shoeb KAZI, Mohammed Hassan DEHGHAN

319 Phytochemical Screening and Establishment of the Antidiabetic Potential of Aqueous Leaf Extract of the Endangered Plant *Decalepis nervosa* in Rats with Alloxan-induced Diabetes
*Alloksan ile İndüklenen Sıçan Diyabet Modelinde Soyu Tükenmekte Olan Decalepis nervosa bitkisinin Sulu Yaprak Ekstraktının Antidiyabetik Potansiyelinin Araştırılması ve Fitokimyasal Taraması*
Kuntal DAS, Saifulla KHAN M, James SOUNDER, Usha MOHAN, Venkatesh PRASADS

329 Anti-inflammatory and Analgesic Effects of *Limnophila repens* (Benth.)
*Limnophila repens (Benth.) Anti-enflamatuvar ve Analjezik Etkileri*
Venkateswarlu GUNJI, Ganapaty SERU

TURKISH
JOURNAL OF PHARMACEUTICAL SCIENCES

## CONTENTS

337 Global DNA Hypomethylation and *Rassf1a* and *c-myc* Promoter Hypermethylation in Rat Kidney Cells after Bisphenol A Exposure
*Bisfenol A Maruziyeti Sonrası Sıçan Böbrek Hücrelerinde Global DNA Hipometilasyonu ve Rassf1a ile c-myc Promotör Hipermetilasyonu*
Pınar TUZCUOĞLU, Sibel ÖZDEN

343 Phytochemical Constituents, Antioxidant Activity, and Toxicity Assessment of the Seed of *Spondias mombin* L. (Anacardiaceae)
*Spondias mombin L. (Anacardiaceae) Tohumunun Fitokimyasal Bileşenleri, Antioksidan Aktivitesi ve Toksisite Değerlendirmesi*
Oyindamola Olajumoke ABIODUN, Mesoma Esther NNORUKA, Rasidat Olufunke TIJANI

349 The Cardiopulmonary Effects of the Calcitonin Gene-related Peptide Family
*Kalsitonin-Geni İle İlişkili Peptit Ailesinin Kardiyopulmoner Etkileri*
Gökçen TELLİ, Banu Cahide TEL, Bülent GÜMÜŞEL

| | |
|---|---|
| PUBLICATION NAME | Turkish Journal of Pharmaceutical Sciences |
| TYPE OF PUBLICATION | Vernacular Publication |
| PERIOD AND LANGUAGE | Bimonthly-English |
| OWNER | Erdoğan ÇOLAK on behalf of the Turkish Pharmacists' Association |
| EDITOR-IN-CHIEF | Prof.Terken BAYDAR, Ph.D. |
| ADDRESS OF PUBLICATION | Turkish Pharmacists' Association, Mustafa Kemal Mah 2147.Sok No:3 06510 Çankaya/ Ankara, TURKEY |

TURKISH
JOURNAL OF PHARMACEUTICAL
SCIENCES

**Volume: 17, No: 3, Year: 2020**

# CONTENTS

***Original articles***

Knowledge and Attitudes Among Hospital Pharmacists About COVID-19
Emre KARA, Kutay DEMİRKAN, Serhat ÜNAL ..... 242

Investigation of the Compressibility Characteristics of Paracetamol using "Compaction Simulator"
Yıldız ÖZALP, Joseph Turemi CHUNU, Nailla JIWA ..... 249

Method Validation of Contact and Immersion TLC-bioautography for Determination of Streptomycin Sulfate in Shrimp
Febri ANNURYANTI, Isnaeni ISNAENI, Asri DARMAWATI, Iftitahatur ROSYIDAH, Aprelita Nurelli DWIANA ..... 254

Microemulsion Based Gel of Sulconazole Nitrate for Topical Application
Sumedha Prashanth PAYYAL, Narayana Charyulu ROMPICHERLA, Sandeep Divate SATHYANARAYANA, Ravi Gundadka SHRIRAM, Anoop Narayanan VADAKKEPUSHPAKATH ..... 259

Obtaining Stem Cell Spheroids from Foreskin Tissue and the Effect of *Corchorus olitorius* L. on Spheroid Proliferation
Eda BECER, Günsu SOYKUT, Hilal KABADAYI, Emil MAMMADOV, İhsan ÇALIŞ, Seda VATANSEVER ..... 265

*In Vitro* Studies of *Jatropha curcas* L. Latex Spray Formulation for Wound Healing Applications
Kittiya TINPUN, Titpawan NAKPHENG, Alwar Ramanujam PADMAVATHI, Teerapol SRICHANA ..... 271

Pyrophen Isolated from the Endophytic Fungus *Aspergillus fumigatus* Strain KARSV04 Synergizes the Effect of Doxorubicin in Killing MCF7 but not T47D Cells
Puji ASTUTI, Ika Buana JANUARTI, Naelaz Zukhruf Wakhidatul KIROMAH, Hidayah Anisa FITRI, Wahyono WAHYONO, Subagus WAHYUONO ..... 280

Sun Protective Potential and Physical Stability of Herbal Sunscreen Developed from Afghan Medicinal Plants
Amina AHMADY, Mohammad Humayoon AMINI, Aqa Mohammad ZHAKFAR, Gulalai BABAK, Mohammad Nasim SEDIQI ..... 285

A Synbiotic Mixture Augmented the Efficacy of Doxepin, Venlafaxine, and Fluvoxamine in a Mouse Model of Depression
Azadeh MESRIPOUR, Andiya MESHKATI, Valiollah HAJHASHEMI ..... 293

*In Vitro* Antimicrobial and Antioxidant Activity of Biogenically Synthesized Palladium and Platinum Nanoparticles Using *Botryococcus braunii*
Anju ARYA, Anju ARYA, Tejpal Singh CHUNDAWAT ..... 299

Mapping the Impact of a Polar Aprotic Solvent on the Microstructure and Dynamic Phase Transition in Glycerol Monooleate/Oleic Acid Systems
Marzuka Shoeb KAZI, Mohammed Hassan DEHGHAN ..... 307

Phytochemical Screening and Establishment of the Antidiabetic Potential of Aqueous Leaf Extract of the Endangered Plant *Decalepis nervosa* in Rats with Alloxan-induced Diabetes
Kuntal DAS, Saifulla KHAN M, James SOUNDER, Usha MOHAN, Venkatesh PRASADS ..... 319

Anti-inflammatory and Analgesic Effects of *Limnophila repens* (Benth.)
Venkateswarlu GUNJI, Ganapaty SERU ..... 329

Global DNA Hypomethylation and *Rassf1a* and *c-myc* Promoter Hypermethylation in Rat Kidney Cells after Bisphenol A Exposure
Pınar TUZCUOĞLU, Sibel ÖZDEN ..... 337

Phytochemical Constituents, Antioxidant Activity, and Toxicity Assessment of the Seed of *Spondias mombin* L. (Anacardiaceae)
Oyindamola Olajumoke ABIODUN, Mesoma Esther NNORUKA, Rasidat Olufunke TIJANI ..... 343

***Review***

The Cardiopulmonary Effects of the Calcitonin Gene-related Peptide Family
Gökçen TELLİ, Banu Cahide TEL, Bülent GÜMÜŞEL ..... 349